The pharmaceutical industry is glued on the FDA hearings on social media happening in the US. The Food and Drug Administration (FDA) is a government agency of the US Department of Health & Human Sciences and acts as the main regulator of US market for drugs, worth $275 billion-a-year.

The hearings are designed to poll expert opinion from a wide range of experts on five key areas:

  • For what online communications are manufacturers, packers or distributors accountable?
  • How can manufacturers, packers or distributors fulfill regulatory requirements in their Internet and social media promotion, particularly when using tools that are associated with space limitations and tools that allow for real-time communications?
  • What parameters should apply to the posting of corrective information on Web sites controlled by third parties?
  • When is the use of links appropriate?
  • How should adverse event reporting be addressed online?

From a web advertising perspective Google and Yahoo! have lobbied for a less restrictive online advertising environment and have started to experiment with new formats of ads to better address the regulatory needs of the US pharmaceutical marketplace.

Google has developed a presentation on its proposed healthcare ad format.

It will be a while before definitive outcomes emerge from these hearings, but the US is taking the lead in considering these issues from a regulatory perspective and it would be great if bodies like the ABPI took a similar approach to dealing with social media issues in the UK.

US-based agencies will develop a valuable advantage through gaining experience in a market that is ahead of the UK in a regulated approach to social media for healthcare clients. You can keep up to date with current developments at these hearings by following the Twitter hashtag #FDASM.

Ged Carroll

Published 16 November, 2009 by Ged Carroll

Ged Carroll is director of digital strategies at Ruder Finn. He is also a trainer and contributor to Econsultancy.

2 more posts from this author

You might be interested in

Comments (2)


Melody at

The results of these hearings should prove to be very interesting. Like most things in the pharmaceutical industry, change is sure to take time but I'm hopeful that resonable recommendations will be put in place.

over 8 years ago


pick your shoes

The results of these hearings should prove to be very interesting. Like most things in the pharmaceutical industry,

over 8 years ago

Save or Cancel

Enjoying this article?

Get more just like this, delivered to your inbox.

Keep up to date with the latest analysis, inspiration and learning from the Econsultancy blog with our free Digital Pulse newsletter. You will receive a hand-picked digest of the latest and greatest articles, as well as snippets of new market data, best practice guides and trends research.